INTRODUCTION

We report a case of stercoral colitis with markedly elevated serum carcinoembryonic antigen (CEA) levels. It should be noted that the serum CEA level can become elevated in severe stercoral colitis. Marked elevation of the serum CEA level in stercoral colitis may suggest the necessity of surgery in patients with stercoral colitis.

Stercoral colitis is an inflammatory condition of the colon caused by fecal impaction. The impacted feces increase intraluminal pressure, leading to ischemia of the bowel that can result in ulceration and subsequent intestinal perforation or ischemic colitis. A history of chronic constipation is a known risk factor for stercoral colitis, and the mortality rate in perforated cases is reported to be 32%-57%. Immediate surgery should be considered in perforated cases and sometimes in nonperforated cases because they can be complicated by ischemic colitis, which can lead to perforation, peritonitis, septic shock, and eventual death if not treated promptly.

Carcinoembryonic antigen (CEA) is a widely used tumor marker for colorectal cancer and various other types of cancer. Serum CEA levels can also be increased in various nonmalignant conditions, including gastrointestinal disorders such as inflammatory bowel disease, and it is reported that ulcerative colitis activity is correlated with serum CEA levels. However, the elevation of serum CEA levels in patients with stercoral colitis has not previously been reported in the English literature.

CASE PRESENTATION

An 80-year-old female who had a history of colon diverticulitis and chronic constipation presented with abdominal pain, vomiting, and diarrhea. At the time of admission, her temperature was 36.4°C, blood pressure was 136/66 mm Hg, pulse rate was 73/min, and respiration rate was 20/min. Physical examination revealed tenderness in her left lower abdomen. Bowel sounds were slightly increased. Muscular defense in the abdomen was not obvious. The results of laboratory tests were as follows: leukocyte count, 14 600/μL, with 80.8% neutrophils; lactate dehydrogenase, 364 IU/l; C-reactive protein, 5.75 mg/dL; creatinine, 0.95 mg/dL; procalcitonin, ≥10.0 ng/mL;
lactate, 60 mEq/L; and CEA, 1240.9 ng/mL. Computed tomography revealed marked fecal impaction in the left colon and rectum, with dilatation of the oral side of the colon (Figure 1). Neither extraluminal gas nor fluid collection was observed.

Emergency operation was performed for the diagnosis of severe stercoral colitis. Lower laparotomy was performed. The proximal descending colon was obstructed by a fecal mass, and the proximal side of the colon was necrotic (Figure 2). Multiple diverticula were found in the descending colon. Extensive colectomy was performed, and the oral side was resected at the terminal ileum and anal side at the sigmoid-descending colon junction using linear staplers. Intraoperative endoscopy from the oral stump of the ileum revealed mucosal necrosis of the distal ileum (Figure 3). The distal ileum was additionally resected, and ileostomy was performed. In the resected specimen, a fecal mass obstructed the descending colon, and the mucosa of the proximal bowel was widely necrotized (Figure 4). The serous surface of the additional resected distal ileum was intact. Histopathological study indicated no malignancy in the resected specimen. Serum CEA levels markedly decreased with time after surgery (Figure 5). The patient survived the operation and remained well 18 months after surgery.
Stercoral colitis is mostly seen in elderly individuals and is more common in old females. It is related to patients being bedridden or having neuropsychiatric disorders, with a poor performance status and a history of chronic constipation along with other comorbidities. Patients with stercoral colitis usually present with abdominal pain and sometimes with distention, nausea, vomiting, melena, or diarrhea. Most patients have elevated white blood cell counts with a shift to the left. Moreover, there may be signs of peritoneal irritation or septic state; however, physical examination or laboratory tests are not always reliable for diagnosing stercoral colitis.

Carcinoembryonic antigen (CEA), a glycoprotein with a molecular weight of approximately 180 kDa, was initially described by Gold and Freedman in 1965. CEA is widely expressed on the surface of tumor cells of various human tissues as well as on the epithelial cells of normal gastrointestinal tissues and fetal intestine. Although CEA mRNA is expressed as actively in normal colon mucosa as in cancer tissues, normal colon mucosa contains a very small quantity of CEA, and the concentration of CEA in normal serum is very low. In the normal colon, single-layered columnar epithelial cells express CEA on the apical surface of cell membranes facing the lumen and rapidly release it into the lumen of the digestive tract, such that CEA does not directly flow into blood capillaries. In contrast, in cancer tissues that have lost single-layer organization, neoplastic cells located deep inside tumor glands express CEA on all sides of the cell surface directly facing the blood vessels.

Smithson et al reported that CEA is upregulated in inflamed human intestinal tissues. Sugarbaker reported markedly elevated serum CEA levels in patients with acute colonic obstruction from colorectal cancer. Bowel decompressive procedures prior to tumor resection markedly reduce serum CEA levels, which suggests that colonic obstruction is independently associated with the elevation of serum CEA levels. Serum CEA levels are rarely greater than 10 ng/mL in benign disorders, and markedly elevated serum CEA levels in patients with colonic obstruction from nonmalignant causes are rarely reported; one of the reasons for this may be that serum CEA levels are rarely measured in benign conditions.

Moreover, when the elevation of serum CEA levels is observed in nonmalignant patients, the existence of cross-reacting antigen with CEA should be considered. The major members of the CEA family antigens include nonspecific cross-reacting antigen (NCA) identified in normal human lung and spleen; NCA-2 in meconium; normal fecal antigen-1 (NFA-1), NFA-2 and normal fecal cross-reacting antigen (NFCA) in normal adult feces; and biliary glycoprotein-1 (BGP-1) in normal bile. Since NCA-2 and NFA-2 have been found to be the same gene products as CEA, they are considered to be normal counterparts of CEA produced by colon epithelial cells of fetuses and by those of normal adults, respectively. The cross-reactivity of commercially available enzyme immunoassay (EIA) kits for CEA differs depending on the products. According to the manufacturers’ data, the EIA kits used in our hospital are reactive with NCA-2 but not with NCA. Unfortunately, there are no data on reactivity with NFAs. While the half-life of CEA in blood is reported to be 4-12 days, the rate of decrease in serum CEA levels in our case was clearly faster than that. Although the half-life times of NFAs are unknown, this finding suggests the possibility of the involvement of NFAs in serum CEA elevation if the EIA kits show cross-reactivity with NFAs.

Considering these findings, we hypothesized that CEA overexpression caused by bowel inflammation might
remain in the intestinal lumen due to fecal colonic obstruction and translocate into blood vessels through damaged intestinal mucosa, resulting in the marked elevation of serum CEA levels in our case. In addition, CEA-related antigens in feces might be involved in serum CEA elevation.

Stercoral colitis often lacks peritoneal irritation symptoms and CT findings of peritonitis, especially in nonperforated cases, which sometimes makes the decision for surgery difficult. However, the delay of surgery can result in fatal outcomes. Therefore, comprehensive judgment is needed for the decision to perform surgery. In addition, marked elevation of serum CEA levels may suggest the severity of stercoral colitis. If computed tomography rules out colorectal cancer and reveals stool impaction, markedly elevated CEA levels may suggest the severe condition of stercoral colitis and may help to determine the indication for surgery.

ACKNOWLEDGMENTS
We thank Dr Tetsuya Ogino for pathological examination.

CONFLICT OF INTEREST
The authors declare that they have no conflicts of interest.

AUTHOR CONTRIBUTIONS
KT: conceived and designed, analyzed and interpreted the data, drafted the article, critically revised the article for important intellectual content, and approved the final manuscript. YT and SU: analysed and interpreted the data and approved the final manuscript. TK: conceived and designed, analyzed and interpreted the manuscript. AK: conceived and approved the final manuscript.

ORCID
Kiyoto Takehara https://orcid.org/0000-0002-3169-2543

REFERENCES
1. Serpell JW, Nicholls RJ. Stercoral perforation of the colon. Br J Surg. 1990;77:1325-1329.
2. Naseer M, Gandhi J, Chams N, Kulairi Z. Stercoral colitis complicated with ischemic colitis: a double-edge sword. BMC Gastroenterol. 2017;17:129.
3. Loewenstein MS, Zamcheck N. Carcinoembryonic antigen (CEA) levels in benign gastrointestinal disease states. Cancer. 1978;42:1412-1418.
4. Zamcheck N, Pusztazeri GCEA. AFP and other potential tumor markers. CA Cancer J Clin. 1975;25:204-214.
5. Begent RH. The value of carcinoembryonic antigen measurement in clinical practice. Ann Clin Biochem. 1984;21(Pt 4):231-238.
6. Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem. 2001;47:624-630.
7. Heffernan C, Pachter HL, Megibow AJ, Macari M. Stercoral colitis leading to fatal peritonitis: CT findings. AJR Am J Roentgenol. 2005;184:1189-1193.
8. Serrano Falcon B, Barcelo Lopez M, Mateos Munoz B, Alvarez Sanchez A, Rey E. Fecal impaction: a systematic review of its medical complications. BMC Geriatr. 2016;16:4.
9. Saksonov M, Bachar GN, Morgenstern S, et al. Stercoral colitis: a lethal disease-computed tomography findings and clinical characteristic. J Comput Assist Tomogr. 2014;38:721-726.
10. Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med. 1965;121:439-462.
11. Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med. 1965;122:467-481.
12. Khare PD, Shao-Xi L, Kuroki M, et al. Specifically targeted killing of carcinoembryonic antigen (CEA)-expressing cells by a retroviral vector displaying single-chain variable fragment antibody to CEA and carrying the gene for inducible nitric oxide synthase. Cancer Res. 2001;61:370-375.
13. Kuroki M, Arakawa F, Yamamoto H, Shimura H, Ikehara Y, Matsuoka Y. Active production and membrane anchoring of carcinoembryonic antigen observed in normal colon mucosa. Cancer Lett. 1988;43:151-157.
14. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. 1999;9:67-81.
15. Smithson JE, Warren BF, Young S, Pigott R, Jewell DP. Heterogeneous expression of carcinoembryonic antigen in the normal colon and upregulation in active ulcerative colitis. J Pathol. 1996;180:146-151.
16. Sugarbaker PH. Carcinoembryonic antigen (CEA) assays in obstructive colorectal cancer. Ann Surg. 1976;184:752-757.
17. von Kleist S, Chavanel G, Burtin P. Identification of an antigen from normal human tissue that crossreacts with the carcinoembryonic antigen. Proc Natl Acad Sci U S A. 1972;69:2492-2494.
18. Mach JP, Pusztazeri G. Carcinoembryonic antigen (CEA): demonstration of a partial identity between CEA and a normal glycoprotein. Immunochemistry. 1972;9:1031-1034.
19. Burtin P, Chavanel G, Hirsch-Marie H. Characterization of a second normal antigen that cross-reacts with CEA. J Immunol. 1950;1973(111):1926-1928.
20. Matsuoka Y, Koga Y, Maruta H, Yoshino M, Tsuru E. Proteolytic release of antigenic fragments corresponding to normal fecal antigen and non-specific cross-reacting antigen from carcinoembryonic antigen. Int J Cancer. 1978;20:604-610.
21. Kuroki M, Koga Y, Matsuoka Y. Purification and characterization of carcinoembryonic antigen-related antigens in normal adult feces. Cancer Res. 1981;41:713-720.
22. Svenberg T. Carcinoembryonic antigen-like substances of human bile. Isolation and partial characterization. Int J Cancer. 1976;17:588-596.
23. Fukushima K, Ohkura T, Kanai M, et al. Carbohydrate structures of a normal counterpart of the carcinoembryonic antigen produced by colon epithelial cells of normal adults. Glycobiology. 1995;5:105-115.
24. Kuroki M, Haruno M, Arakawa F, Wakisaka M, Matsuoka Y. Reaction profiles of seven enzyme immunoassay kits for carcinoembryonic antigen (CEA) analyzed with purified preparations of CEA and related normal antigens. Clin Biochem. 1992;25:29-35.
25. Choi JS, Min JS. Significance of postoperative serum level of carcinoembryonic antigen (CEA) and actual half life of CEA in colorectal cancer patients. *Yonsei Med J*. 1997;38:1-7.

26. Kumamoto K, Ishida H, Kuwabara K, et al. Clinical significance of serum anti-p53 antibody expression following curative surgery for colorectal cancer. *Mol Clin Oncol*. 2017;7:595-600.

27. Ito K, Hibi K, Ando H, et al. Usefulness of analytical CEA doubling time and half-life time for overlooked synchronous metastases in colorectal carcinoma. *Jpn J Clin Oncol*. 2002;32:54-58.

**How to cite this article:** Takehara K, Takehara Y, Ueyama S, Kobayashi T. A case of stercoral colitis with marked elevation of serum carcinoembryonic antigen. *Clin Case Rep*. 2020;8:734–738. [https://doi.org/10.1002/ccr3.2739](https://doi.org/10.1002/ccr3.2739)